ID   WRO
AC   CVCL_0582
AS   CVCL_1663
SY   WRO82-1; WRO 82-1; WRO-82; WRO82; UCLA RO 82-W-1; UCLA RO-82W-1; UCLA RO82W1; RO82W1; RO 82 W-1; RO82-W-1; RO82W-1; RO82
DR   BTO; BTO:0004772
DR   CLO; CLO_0008860
DR   MCCL; MCC:0000488
DR   CLDB; cl4167
DR   CLDB; cl4902
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_0582
DR   Cell_Model_Passport; SIDM00218
DR   ChEMBL-Cells; CHEMBL3308779
DR   ChEMBL-Targets; CHEMBL1075565
DR   Cosmic; 684194
DR   Cosmic; 685606
DR   Cosmic; 849971
DR   Cosmic; 886554
DR   Cosmic; 918181
DR   Cosmic; 928830
DR   Cosmic; 930083
DR   Cosmic; 931244
DR   Cosmic; 990535
DR   Cosmic; 1005459
DR   Cosmic; 1094762
DR   Cosmic; 1152113
DR   Cosmic; 1155332
DR   Cosmic; 1161614
DR   Cosmic; 1162842
DR   Cosmic; 1280051
DR   Cosmic; 1699415
DR   Cosmic; 2319849
DR   Cosmic-CLP; 930083
DR   DepMap; ACH-001384
DR   ECACC; 92030502
DR   EGA; EGAS00001000978
DR   GDSC; 930083
DR   GEO; GSM827437
DR   GEO; GSM1670384
DR   IARC_TP53; 2130
DR   IARC_TP53; 27230
DR   ICLC; HTL98002
DR   LINCS_LDP; LCL-1680
DR   Lonza; 1209
DR   PharmacoDB; RO82W1_1322_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0582
DR   PubChem_Cell_line; CVCL_0582
DR   TOKU-E; 4066
DR   Wikidata; Q54994417
RX   PubMed=2551628;
RX   PubMed=2570483;
RX   PubMed=8423216;
RX   PubMed=9348181;
RX   PubMed=11439348;
RX   PubMed=14522906;
RX   PubMed=16778181;
RX   PubMed=17804723;
RX   PubMed=18713817;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=23162534;
RX   PubMed=25675381;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: 4 days (PubMed=2570483).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23162534).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Homozygous (PubMed=8423216; PubMed=14522906; Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Mitochondrial genome sequenced.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=2.33%; Native American=0%; East Asian, North=1.32%; East Asian, South=3.34%; South Asian=7.27%; European, North=24%; European, South=61.74% (PubMed=30894373).
CC   Derived from site: Metastatic; Not specified.
ST   Source(s): Cosmic-CLP; DepMap; ICLC
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 9
ST   D16S539: 11,12 (DepMap; ICLC)
ST   D16S539: 12 (Cosmic-CLP)
ST   D18S51: 10,13
ST   D21S11: 29
ST   D3S1358: 14,15
ST   D5S818: 12
ST   D7S820: 8,12
ST   D8S1179: 11,16
ST   FGA: 22.2,23
ST   Penta D: 10
ST   Penta E: 19,20
ST   TH01: 7,9.3
ST   TPOX: 8
ST   vWA: 16,19 (Cosmic-CLP; DepMap)
ST   vWA: 16,21 (ICLC)
DI   NCIt; C8054; Thyroid gland follicular carcinoma
DI   ORDO; Orphanet_146; Differentiated thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 37
//
RX   PubMed=2551628; DOI=10.1210/endo-125-4-1783;
RA   Pang X.-P., Hershman J.M., Chung M., Pekary A.E.;
RT   "Characterization of tumor necrosis factor-alpha receptors in human
RT   and rat thyroid cells and regulation of the receptors by
RT   thyrotropin.";
RL   Endocrinology 125:1783-1788(1989).
//
RX   PubMed=2570483; DOI=10.1007/BF02899078;
RA   Estour B., Van Herle A.J., Juillard G.J.-F., Totanes T.L.,
RA   Sparkes R.S., Giuliano A.E., Klandorf H.;
RT   "Characterization of a human follicular thyroid carcinoma cell line
RT   (UCLA RO 82 W-1).";
RL   Virchows Arch. B. Cell. Pathol. Incl. Mol. Pathol. 57:167-174(1989).
//
RX   PubMed=8423216; DOI=10.1172/JCI116168;
RA   Fagin J.A., Matsuo K., Karmakar A., Chen D.-L., Tang S.-H.,
RA   Koeffler H.P.;
RT   "High prevalence of mutations of the p53 gene in poorly differentiated
RT   human thyroid carcinomas.";
RL   J. Clin. Invest. 91:179-184(1993).
//
RX   PubMed=9348181; DOI=10.1210/endo.138.11.5509;
RA   Nishihara E., Nagayama Y., Mawatari F., Tanaka K., Namba H., Niwa M.,
RA   Yamashita S.;
RT   "Retrovirus-mediated herpes simplex virus thymidine kinase gene
RT   transduction renders human thyroid carcinoma cell lines sensitive to
RT   ganciclovir and radiation in vitro and in vivo.";
RL   Endocrinology 138:4577-4583(1997).
//
RX   PubMed=11439348; DOI=10.1038/sj.onc.1204531;
RA   Frasca F., Vigneri P., Vella V., Vigneri R., Wang J.Y.-J.;
RT   "Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile
RT   response to hepatocyte growth factor.";
RL   Oncogene 20:3845-3856(2001).
//
RX   PubMed=14522906;
RA   Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R.,
RA   Vigneri P.;
RT   "p73 tumor-suppressor activity is impaired in human thyroid cancer.";
RL   Cancer Res. 63:5829-5837(2003).
//
RX   PubMed=16778181; DOI=10.1158/0008-5472.CAN-06-0171;
RA   Bonora E., Porcelli A.M., Gasparre G., Biondi A., Ghelli A.,
RA   Carelli V., Baracca A., Tallini G., Martinuzzi A., Lenaz G.,
RA   Rugolo M., Romeo G.;
RT   "Defective oxidative phosphorylation in thyroid oncocytic carcinoma is
RT   associated with pathogenic mitochondrial DNA mutations affecting
RT   complexes I and III.";
RL   Cancer Res. 66:6087-6096(2006).
//
RX   PubMed=17804723; DOI=10.1158/0008-5472.CAN-06-4026;
RA   van Staveren W.C.G., Weiss-Solis D.Y., Delys L., Duprez L., Andry G.,
RA   Franc B., Thomas G., Libert F., Dumont J.E., Detours V., Maenhaut C.;
RT   "Human thyroid tumor cell lines derived from different tumor types
RT   present a common dedifferentiated phenotype.";
RL   Cancer Res. 67:8113-8120(2007).
//
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102;
RA   Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M.,
RA   Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. III, Smallridge R.C.,
RA   Haugen B.R.;
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=23162534; DOI=10.3389/fendo.2012.00133;
RA   Saiselet M., Floor S., Tarabichi M., Dom G., Hebrant A.,
RA   van Staveren W.C.G., Maenhaut C.;
RT   "Thyroid cancer cell lines: an overview.";
RL   Front. Endocrinol. 3:133.1-133.9(2012).
//
RX   PubMed=25675381; DOI=10.1210/jc.2014-2764;
RA   von Roemeling C.A., Marlow L.A., Pinkerton A.B., Crist A., Miller J.,
RA   Tun H.W., Smallridge R.C., Copland J.A. III;
RT   "Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals
RT   stearoyl CoA desaturase 1 as a novel therapeutic target.";
RL   J. Clin. Endocrinol. Metab. 100:E697-E709(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//